Drug intelligence / Profile preview

VP-004

Development stage: Preclinical
Lead developer: Varsity Pharmaceuticals
Modality: Small Molecules

Overview

VP-004 is a small molecule inhibitor targeting Protein Kinase C (PKC), currently under development by Varsity Pharmaceuticals. It is specifically being investigated for the treatment of Chronic Lymphocytic Leukemia (CLL). PKC is a family of serine/threonine kinases that play a pivotal role in various cellular signaling pathways, including those governing cell growth, differentiation, and survival. In CLL, PKC signaling (particularly the PKC-beta isoform) is a critical component of the B-cell receptor (BCR) signaling pathway, which promotes the survival and proliferation of malignant B cells. By inhibiting PKC, VP-004 aims to disrupt these survival signals and induce apoptosis in leukemic cells.

Targets

PKC (Protein kinase C family)

Beyond the preview

Go deeper on VP-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VP-004.

Explore the full profile